Claims
- 1. A method of treating a patient in need of analgesic relief which comprises administering to said patient an effective analgesic amount of a compound having the formula; ##STR10## the enantiomeric forms and mixtures thereof, and the pharmaceutically acceptable salts thereof wherein the dotted lines represent facultative double bonds, R.sub.1 is H, F, Cl, C.sub.1-6 alkyl, OH, C.sub.1-6 alkoxy, C.sub.1-6 alkyl thio, C.sub.1-6 acylamino, or C.sub.1-6 acyloxy; R.sub.2 is H, Cl, F or C.sub.1-6 alkyl; each of R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is H, Cl, F, C.sub.1-6 alkyl, C.sub.1-6 alkylamino, C.sub.1-6 alkoxy, aryl or aralkyl; and when R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, and R.sub.8 and R.sub.9 are taken together with the carbon atoms to which they are attached form a 5-6 membered carbocyclic moiety, with the proviso that the number of so-formed carbocyclic moieties is limited to less than 3, and with the further proviso that when the depicted ring moiety having the facultative double bonds is saturated then any 5-6 membered carbocyclic moiety formed therewith is also saturated.
- 2. A method according to claim 1 wherein R.sub.1 is H, F, Cl, C.sub.1-6 alkyl, OH or C.sub.1-6 alkoxy; R.sub.2 is H, Cl, F or C.sub.1-6 alkyl; each of R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is H, Cl, F or C.sub.1-6 alkyl; and when R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, and R.sub.8 and R.sub.9 are taken together with the carbon atoms to which they are attached, they form a 6-membered carbocyclic moiety with the proviso that when the depicted ring moiety having the facultative double bonds is saturated R.sub.1, R.sub.2, R.sub.6 R.sub.7,R.sub.8, and R.sub.9 cannot all be hydrogen, and with the further proviso that when the depicted ring moiety having the facultative double bonds is saturated then the 6-membered carbocyclic moiety formed is also saturated.
- 3. A method according to claim 1 wherein R.sub.1 and R.sub.2 are hydrogen.
- 4. A method according to claim 1 wherein R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are hydrogen.
- 5. A method according to claim 1 wherein R.sub.6 and R.sub.7, together with the carbon atoms to which they are attached, form a 3-amino-1,2-dihydro-2(1H)phenanthrenone.
- 6. A method according to claim 1 wherein R.sub.8 and R.sub.9, together with the carbon atoms to which they are attached, form a 2-amino-1,2-dihydro-3(4H)phenanthrenone.
- 7. A pharmaceutical composition comprising having a therapeutically effective amount of a compound having the formula ##STR11## The enantiomeric forms and mixtures thereof, and the pharmaceutically acceptable salts thereof wherein the dotted lines represent facultative double bonds, R.sub.1 is H, F, Cl, C.sub.1-6 alkyl, OH, C.sub.1-6 alkyl thio, C.sub.1-6 acylamino, or C.sub.1-6 acyloxy; R.sub.2 is H, Cl, F or C.sub.1-6 alkyl; each of R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is H, Cl, F, C.sub.1-6 alkyl, C.sub.1-6 alkylamino, C.sub.1-6 alkoxy, aryl or aralkyl; and when R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, and R.sub.8 and R.sub.9 are taken together with the carbon atoms to which they are attached form a 5-6 membered carbocyclic moiety, with the proviso that the number of so-formed carbocyclic moieties is limited to less than 3, and with the further proviso that when the depicted ring moiety having the facultative double bonds is saturated then any 5-6 membered carbocyclic moiety formed therewith is also saturated in combination with a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition comprising having a therapeutically effective amount of a compound having the formula R.sub.1 is H, F, Cl, C.sub.1-6 alkyl, OH or C.sub.1-6 alkoxy, R.sub.2 is H, Cl, F or C.sub.1-6 alkyl, each of R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is H, Cl, F or C.sub.1-6 alkyl, and when R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, and R.sub.8 and R.sub.9 are taken together with the carbon atoms to which they are attached, they form a 6-membered carbocyclic moiety with the proviso that when the depicted ring moiety having the facultative double bonds is saturated R.sub.1, R.sub.2, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 cannot all be hydrogen, and with the further proviso that when the depicted ring moiety having the facultative double bonds is saturated then the 6-membered carbocyclic moiety formed is also saturated in combination with a pharmaceutically acceptable carrier.
Parent Case Info
This is a divisional of application Ser. No. 07/460,693, filed Jan. 4, 1990, U.S. Pat. No. 5,041,673.
Divisions (1)
|
Number |
Date |
Country |
Parent |
460693 |
Jan 1990 |
|